New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).
The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says. GLP-1 ...
Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic for diabetes and Wegovy for weight loss, has ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
MedPage Today on MSN1d
ObesityWeek Roundup: Patients More Likely to Ration Weight-Loss DrugsSAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...
Dallas Morning News on MSN5d
FDA adds new warning to weight loss drugs including WegovyThe FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...
Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) prior to bariatric surgery was safe but wasn’t associated with ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
GLP-1, SGLT2 medications may lower risk of future MI and repeat stroke among stroke survivors: Study
GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback